The latest from CDMOs, CMOs, and suppliers featuring Olon, BioCina, Noramco and Cambrex.  

Chemicals/Chemical API Manufacturing 
* Olon To Invest $10.7 M to Expand India API Mfg Site  
Biologics Manufacturing 
* BioCina, GPN Vaccines Expand Vaccine Partnership  
Formulation Development/Drug Product Manufacturing 
* Noramco Completes Acquisition of Drug Product Business of Cambrex
* Roquette Completes Acquisition of Qualicap 

---

Chemicals/Chemical API Manufacturing 

Olon To Invest $10.7 M to Expand India API Mfg Site  
Olon, a CDMO of active pharmaceutical ingredients (APIs) and intermediates, has announced a EUR 10 million ($10.7 million) multi-year expansion plan for its production site in Mahad, India. 

The expansion will increase the plant’s total production capacity by 45% in chemical synthesis. The new production line will include reactors and filter dryers equipped with all necessary utilities, and will come into operation in the second quarter of 2024, allowing for gradual further capacity growth until 2026. 

Source: Olon 

---

Biologics Manufacturing 

BioCina, GPN Vaccines Expand Vaccine Partnership  
BioCina, an Adelaide, Australia-based CDMO of biologics, have expanded their partnership with GPN Vaccines, a bio/pharmaceutical company. 

GPN Vaccines is developing an engineered whole-cell vaccine called Gamma-PNTM against Streptococcus pneumoniae. This bacterium is responsible for causing life-threatening infections such as pneumonia, bacteraemia and meningitis, each year causing up to 2 million deaths worldwide.  

BioCina will manufacture large-scale cGMP batches for this program at BioCina’s facility in Adelaide, Australia. 

Source: BioCina 

---

Formulation Development/Drug Product Manufacturing 

Noramco Completes Acquisition of Drug Product Business of Cambrex 
Noramco, a CDMO of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. 

The acquisition will provide Noramco, and its subsidiary Purisys, additional service options such as drug product formulation development, clinical and commercial drug product manufacturing, and packaging from facilities in Mirabel, Québec and Whippany, New Jersey. Noramco is returning to the Halo Pharmaceutical brand as part of this acquisition. 

Source: Noramco 

---

Roquette Completes Acquisition of Qualicaps 
Roquette has completed its acquisition of Qualicaps, a manufacturer of hard capsules and pharmaceutical related equipment, from the Mitsubishi Chemical Group. 

Qualicaps is a manufacturer of hard capsules and pharmaceutical related equipment and is the third largest producer of hard capsules for oral dosage solutions. The company has a workforce of 1,400 employees located in different sites in Asia, Europe and the Americas. 

Source: Roquette